Using diuretics in practice - One opinion

Journal of Clinical Hypertension

Volumn 10, Issue 11, 2008, Pages 856-862

  Elliott, William J ^a,b   Grimm Jr , Richard H ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BUMETANIDE; CENTRAL DEPRESSANT AGENT; CHLORTALIDONE; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LITHIUM; LOOP DIURETIC AGENT; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DIABETES MELLITUS; DIURETIC THERAPY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG USE; ERECTILE DYSFUNCTION; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOCALCEMIA; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; BLOOD PRESSURE; DRUG EFFECT; STATISTICS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; DIURETICS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS;

EID: 58149475972     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00029.x     Document Type: Article

References (57)

1. Whitworth JA, for the World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003; 21: 1983-1992.
2. National Institute for Health and Clinical Excellence. Hypertension: Management of Hypertension in Adults in Primary Care, a Partial Update of NICE Clinical Guideline 18; pp. 1-45, issued 28 June, 2006. http://www.nice.org.uk/nicemedia/pdf.CG034NICEguideline.pdf. Accessed October 16, 2008.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. Task force for the management of arterial hypertension of the European Society of hypertension and the European Society of cardiology. J Hypertens. 2007; 25: 1105-1187.
4. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289: 2560-2572.
5. The ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967-1975.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
7. Elliott WJ. Systemic hypertension. Curr Prob Cardiol. 2007; 32: 201-259.
8. Standards of Medical Care in Diabetes -2007 (Technical Review). Diabetes Care. 2007; 30 (Suppl1): S4-S41.
9. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition in diabetic nephropathy. N Engl J Med. 1993; 323: 1456-1462.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. Collaborative Study Group. N Engl J Med. 2001; 345: 851-860.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. Reduction of endpoints in non-insulin dependent diabetes mellitus with the angiotensin II antagonist losartan (RENAAL) Study Group. N Engl J Med. 2001; 345: 861-869.
12. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med. 2003; 139: 244-252.
13. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med. 2005; 165: 936-946.
14. Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006; 144: 172-180.
15. The SHEP Cooperative Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991; 265: 3255-3264.
16. Staessen JA, Fagard R, Thijs L, et al. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997; 360: 757-764.
17. Liu L, Wang J, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998; 16: 1823-1829.
18. Moser M, Setaro JF. Resistant or difficult-to-control hypertension. N Engl J Med. 2006; 355: 385-392.
19. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-1041.
20. Wall GC, Gibner D, Craig S. Ethacrynic acid and the sulfa-sensitive patient. Arch Intern Med. 2003; 163: 116-117.
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
22. Levey AS, Rocco MV, Anderson S, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43 (suppl 1): S1-S290.
23. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995; 26: 394-400.
24. Shem S. The House of God. New York, NY: Dell Publishing; 1979.
25. Top 200 generic drugs by units in 2006. http://www.drugtopics.com/ drugtopics.modernmedicine/data/articlestandard/drugtopics/092007/407652/ article.pdf. Accessed October 16, 2008.
26. Bowlus WE, Langford HG. A comparison of the antihypertensive effect of chlorthalidone and hydrochlorothiazide. Clin Pharmacol Ther. 1964; 5: 708-711.
27. Finnerty FA Jr. A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensives. Angiology. 1976; 27: 738-744.
28. Clark EC, Podolsky S, Thompson EJ. Double-blind comparison of hydrochlorothiazide plus triamterene therapy versus chlorthalidone therapy in hypertension. South Med J. 1979; 72: 798-802.
29. van Soeren F. The antihypertensive and biochemical effects of hydrochlorothiazide/amiloride (Moduretic) versus chlorthalidone. J Int Med Res. 1980; 8: 132-135.
30. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006; 47: 352-358.
31. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone. Evidence supporting their interchangeability. Hypertension. 2004; 43: 4-9.
32. Khosla N, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood pressure-lowering medications? J Clin Hypertens (Greenwich). 2005; 7: 354-356.
33. Hypertension Detection and Follow-up Cooperative Group. Persistence of reduction in blood pressure and mortality in participants in the Hypertension Detection and Follow-Up Program. JAMA. 1988; 259: 2113-2122.
34. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressure averaging 115 through 129mm Hg. JAMA. 1967; 202: 1028-1034.
35. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990; 82: 1616-1628.
36. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: Main result from the HAPPHY trial. J Hypertension. 1987; 5: 560-572.
37. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study: Final results. JAMA. 1993; 270: 713-724.
38. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988; 259: 1976-1982.
39. Agabiti-Rosei E, Dal PalùC, Leonetti G, et al. Clinical results of the verapamil in hypertension and atherosclerosis study. The VHAS investigators. J Hypertens. 1997; 15: 1337-1344.
40. MRC Working Party. Medical Research Council Trial of Treatment of Hypertension in Older Adults: Principal results. BMJ. 1992; 304: 405-412.
41. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomized trial. JAMA. 1996; 276: 785-791.
42. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet. 2000; 356: 366-372.
43. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995; 108: 710-717.
44. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA. 2003; 289: 2073-2082.
45. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. Second Australian National Blood Pressure Study Group. N Engl J Med. 2003; 348: 583-592.
46. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low dose diuretic therapies. JAMA. 2004; 292: 43-44.
47. Bartsch G, Broste S, Grandits G, et al. Hydrochlorothiazide, chlorthalidone and mortality in the Multiple Risk Factor Intervention Trial [abstract]. Circulation. 1984; 70 (suppl II): II-1438.
48. Kolata G. Heart study produces a surprise result. Science. 1982; 218: 31-32.
49. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004; 43: 963-969.
50. Almgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: Results from a 28-year follow-up. J Hypertens. 2007; 25: 1311-1317.
51. Aksnes TA, Kjeldsen SE, Rostrup M, et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population. Hypertension. 2007; 50: 467-473.
52. Fox CS, Sullivan L, D'Agostino RB Sr, et al. The significant effect of diabetes duration on coronary heart disease mortality: The Framingham Heart Study. Diabetes Care. 2004; 27: 704-708.
53. Dunder K, Lind L, Zethelius B, et al. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: Population-based cohort study. BMJ. 2003; 326: 681-684.
54. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005; 95: 29-35.
55. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006; 166: 2191-2201.
56. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet. 2007; 369: 201-207. erratum 1518.
57. Biucca CB, Brussino L, Battistia A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest. 2007; 132: 440-446.